Upstream Bio, Inc. Common Stock (UPB) is a publicly traded Healthcare sector company. As of July 27, 2026, UPB trades at $6.38 with a market cap of $348.83M and a P/E ratio of -2.41. UPB moved -0.47% today. Year to date, UPB is -76.54%; over the trailing twelve months it is -51.98%. Its 52-week range spans $5.14 to $33.68. Analyst consensus is strong buy with an average price target of $42.33. Rallies surfaces UPB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Verekitug Achieves 79% NPS Response and 83% Symptom Score Improvement: Upstream Bio’s Phase 2 VIBRANT trial showed quarterly verekitug dosing achieved NPS improvements in 79% of participants versus 24% for placebo, with 72% improving nasal congestion and 83% reducing total symptom score. The therapy had no serious adverse events and Phase 3 trials are set to start in Q1 2027.
| Metric | Value |
|---|---|
| Price | $6.38 |
| Market Cap | $348.83M |
| P/E Ratio | -2.41 |
| EPS | $-2.66 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.68 |
| 52-Week Low | $5.14 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.85M |
| Net Income | $-143.44M |
| Gross Margin | 0.00% |
8 analysts cover UPB: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $42.33.